The revision is a step toward finalizing the transition from Paxlovid’s emergency use authorization to its new drug application label, initiated in late 2023.
About a quarter of American adults said they ‘personally know someone’ who they believe was killed by COVID-19 vaccine-related side effects, a survey shows.